Taking Greater Control of Rx Costs: A Case Study

March 26, 2020

Tired of efforts to lower pharmacy costs having little impact on the bottom line? Plan sponsors are growing frustrated as the industry continues to find ways to add cost without adding value.

According to a recent study, 85% of employers said that pharmacy pricing was their predominant concern going into 2020.1 In the U.S. healthcare system, the estimated cost of waste ranges from $760 billion to $935 billion, or about 25% of total healthcare spending, according to a recent report in JAMA.2 Even one high-cost drug can consume a significant portion of a health care budget, making it increasingly important for plan sponsors to find more cost-effective drug solutions to reduce waste and unnecessary expenses.

It’s time to start taking control of pharmacy benefit costs. Find out how one plan went from year-over-year double-digit trend increases to achieving a less than 3% average increase over six years.

Navigating Complex Pharmacy Benefits

Self-Insured Schools of California (SISC) was diligent about keeping benefit costs affordable and stable by pooling the resources of its over 400 member school districts in 43 counties across California. Despite its actions to lower pharmacy costs, SISC grew tired of its efforts having little impact. SISC knew it needed a new perspective with more transparency and clarity to enhance its pharmacy benefit strategy.

Uncovering Significant Savings Opportunities

With the help of its consultant, SISC decided to partner with Navitus. Instead of increasing its spend by covering more expensive drugs to get higher rebates, SISC wanted to establish a high-performance formulary with clinically effective alternatives at the lowest net cost.

Reducing Costs and Maintaining Member Access to Care

By making a few changes, SISC was able to eliminate waste and lower costs while ensuring members received the most clinically appropriate, safe and cost-effective medications. As a result, SISC has maintained strong benefits that allow members to continue to have affordable access to the therapies they need.

Want to see the results?

Download the full case study to find out how SISC removed over 600 unnecessary drugs from the formulary with minimal member impact.

Despite its actions to lower pharmacy costs, SISC grew tired of its efforts having little impact on the bottom line. It was time for a new perspective with more transparency and clarity to enhance its pharmacy benefit strategy.

With the help of its consultant, SISC decided to partner with Navitus to establish a high-performance formulary with clinically effective alternatives at the lowest net cost.

SISC saw a significant decrease in total net cost PMPM in the first year, and maintained nearly flat costs in each succeeding year.

Download the FULL case study to learn more


Waddill, K. Employers Focus on High-Cost Claims, Drug Spending into 2020. Health Payer Intelligence. https://healthpayerintelligence.com/news/employers-focus-on-high-cost-claims-drug-spending-into-2020. Published August 15, 2019. Accessed February 12, 2020.

Elfin, D. Waste Gobbles up 25% of US Healthcare Spending, JAMA Study Finds. Healthcare Dive. https://www.healthcaredive.com/news/waste-gobbles-up-25-of-us-healthcare-spending-jama-study-finds/564433/. Published October 7, 2019. Accessed February 12, 2020. 

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow